Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford's Colorectal Cancer Stratified Medicine Network

Colorectal cancer (CRC) remains the second most common cause of cancer death, and patients with stage 3/4 cancers at diagnosis only have a 10% survival rate at 5 years.

CRC presents an opportunity for precision medicine as it is common cancer, has known and established driver molecular pathways, and pre-treatment molecular stratification is achievable.

ACRCelerate brings together a European-wide consortium of researchers at the forefront of CRC research. Researchers Prof Simon Leedham and Prof Tim Maughan lead the work from Oxford, collaborating with researchers across the UK, Italy and Spain.

The overall aim of the consortium is to generate robust and reproducible preclinical data to de-risk future clinical trials based on patient stratification. This will be achieved through:

  • developing preclinical models that recapitulate the molecular subtypes of CRC and characterising their signalling pathways
  • using DNA and RNA sequencing to subtype the models, identify and test new therapeutics
  • integrating data in a bioinformatic analysis pipeline

This research is currently funded by CRUK.

Existing collaborations across the network. The hubs of the network are shown with their existing internal and external collaborationsExisting collaborations across the network. The hubs of the network are shown with their existing internal and external collaborations

This international network prevents proprietary duplication of work, enhances collaboration and training and facilitates result validation.This international network prevents proprietary duplication of work, enhances collaboration and training and facilitates result validation.

Colorectal Cancer News

Eoghan Mulholland awarded colorectal cancer fellowship

As part of UK Pride month, we are spotlighting the work of cancer researcher and University LGBTQ+ Representative Dr Eoghan Mulholland

Bowel cancer patients going undiagnosed due to COVID distruption

A new study led by the University of Oxford has found that since the first coronavirus lockdown the number of people diagnosed with bowel cancer in England has fallen sharply, with a deficit persisting up to October 2020.

IL-22 pathway linked to poor prognosis in colon cancer

Research shows how IL-22 interacts with KRAS mutant tumours to promote excessive growth in colorectal cancer